New combo pill targets Hard-to-Treat prostate cancer in men with SPOP mutation

NCT ID NCT05689021

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This phase 2 trial tests a fixed-dose combination of niraparib and abiraterone acetate plus prednisone in 8 men with metastatic castration-resistant prostate cancer that has a SPOP gene mutation. The drugs work by blocking cancer cell repair and reducing inflammation. The main goal is to see if PSA levels drop by at least 50%.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Niraparib and abiraterone acetate fixed-dose combination plus prednisone
What this could lead to: If successful, this could offer a new targeted treatment option for men with a specific genetic mutation (SPOP) in advanced prostate cancer.
What could go wrong: This is a very small phase 2 trial with only 8 participants, so results may not apply broadly. The drug combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Show contact details

Locations

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.